Indianapolis-based drug maker Eli Lilly and German pharmaceutical company Boehringer Ingelheim have achieved a significant milestone in the treatment of diabetes. The U.S. Food and Drug Administration (FDA) has granted expanded approval for their blockbuster drug Jardiance, specifically designed for certain adults with chronic kidney disease.
The FDA approval encompasses the use of Jardiance to mitigate various risks associated with chronic kidney disease, particularly the decline in estimated glomerular filtration rate, end-stage kidney disease, cardiovascular death, and hospitalization. This breakthrough treatment focuses on adults with chronic kidney disease who are at risk of progression.
In a strategic partnership established back in 2011, Eli Lilly and Boehringer Ingelheim jointly market Jardiance. The drug was initially approved by the FDA in 2014 for treating adults with type 2 diabetes. Subsequently, it received approval for reducing the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease. It was also approved for reducing the risk of death and hospitalization in adults with heart failure.
Eli Lilly reported remarkable revenue of nearly $1.25 billion for Jardiance in the first six months of this year alone, showcasing its immense success and impact in the healthcare industry.
This expanded FDA approval is an exceptional advancement in diabetes treatment, elevating the hope for a better quality of life for adults suffering from chronic kidney disease. With Jardiance paving the way, patients can anticipate a reduction in risks associated with this condition, promoting improved overall health and well-being.